Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Invested Capital (2019 - 2025)

Historic Invested Capital for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $74.3 million.

  • BridgeBio Pharma's Invested Capital rose 10609.23% to $74.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.3 million, marking a year-over-year increase of 10609.23%. This contributed to the annual value of -$729.0 million for FY2024, which is 4616.74% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Invested Capital is $74.3 million, which was up 10609.23% from -$1.8 billion recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Invested Capital registered a high of $358.1 million during Q1 2021, and its lowest value of -$1.8 billion during Q2 2025.
  • For the 5-year period, BridgeBio Pharma's Invested Capital averaged around -$904.1 million, with its median value being -$1.1 billion (2024).
  • As far as peak fluctuations go, BridgeBio Pharma's Invested Capital crashed by 1312673.52% in 2022, and later surged by 10609.23% in 2025.
  • BridgeBio Pharma's Invested Capital (Quarter) stood at -$867.0 million in 2021, then crashed by 43.41% to -$1.2 billion in 2022, then fell by 8.92% to -$1.4 billion in 2023, then soared by 46.17% to -$729.0 million in 2024, then soared by 110.19% to $74.3 million in 2025.
  • Its last three reported values are $74.3 million in Q3 2025, -$1.8 billion for Q2 2025, and -$1.6 billion during Q1 2025.